Browsing for next random stock pick!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BODY - On my radar again. I think it has cooled down. Will be watching it's PPS tomorrow here.
INUV ($0.92) Inuvo Inc. to Present at LD Micro Conference on June 4th
Chairman and CEO, will be a featured presenter at the LD Micro Conference Wednesday, June 4th, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
REF. http://finance.yahoo.com/news/inuvo-inc-present-ld-micro-130000434.html
Waiting for this to relax/chill and cool down. Perhaps $.70 I have my opportunity.
MCZ ($0.67)- Mad Catz® to Report Fiscal 2014 Fourth Quarter Results on June 5 and Host Conference Call and Webcast
Mad Catz Interactive, Inc. (“Mad Catz”) (NYSE MKT/TSX: MCZ) announced today it will release its fiscal 2014 fourth quarter results for the period ended March 31, 2014, after the market closes on Thursday, June 5, 2014, and will host a conference call and webcast at 5:00 p.m. ET that same day. Both the call and webcast are open to the general public.
Ref. http://finance.yahoo.com/news/mad-catz-report-fiscal-2014-113500486.html
IDN ($0.75) This is like clock work....20-.25 easily it seems.
SYN - Ned - I think I am going to give this till end of this month then I am out. I will attempt to average one more time before taking off table here.
ARQL ($1.38) Price check. Something's up for June here (included in previous June's FDA list etc.) Please also check insiders buying with this one.
Previous news: ArQule Inc. (ARQL) in Focus: Stock Rises 8.21% ref. http://finance.yahoo.com/news/arqule-inc-arql-focus-stock-103514877.html
BOARD: Some Upcoming June FDA Approval (PDUFA Dates. Feel free to browse through see if anything is out-there.
BDSI PDUFA (06.07.2014) Ref. http://bdsi.investorroom.com/2013-11-12-BioDelivery-Sciences-Provides-Business-Review-and-Update-in-Conjunction-with-Filing-of-Third-Quarter-2013-Financials
OREX PDUFA (06.10.2014) Ref. http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle&ID=1888545&highlight=
NAVB PDUFA (06.15.2014) Ref. http://ir.navidea.com/phoenix.zhtml?c=68527&p=irol-newsArticle&ID=1900630&highlight=
ETRM Advisory Committee (06.17.2014) Ref. http://ir.enteromedics.com/releasedetail.cfm?ReleaseID=831439
ACST Phase 2 (06.30.2014) Ref.http://www.acastipharma.com/en/investor-relations/press-releases/170-acasti-announces-third-quarter-results
ACHN (06.17.2014) Ref. http://ir.achillion.com/releaseDetail.cfm?ReleaseID=818759
ANTH Phase 3 (06.30.2014) Ref. http://investor.anthera.com/releasedetail.cfm?ReleaseID=801392
ARQL Phase 2 (06.30.2014)
BLRX Phase 2 (06.30.2014) Ref. http://ir.biolinerx.com/phoenix.zhtml?c=208785&p=irol-newsArticle&ID=1907397&highlight=
CORT Phase 2 (06.30.2014) http://www.corcept.com/news_events/view/pr_1391118469
CPRX ($2.19) Reminder Catalyst's Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Thursday, June 5th at 2:00 pm ET.
Looking for possible breakout above $1.86. This could have a target of $2.34 (near term). I will take $2.30 though..
Nice close today!
ASTM ($4.22) Still room to wiggle around. Aastrom Completes Acquisition of Sanofi's Cell Therapy and Regenerative Medicine Business
ANN ARBOR, Mich., June 2, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that the company has completed its acquisition of Sanofi's cell therapy and regenerative medicine (CTRM) business unit. As announced on April 21, 2014, Aastrom paid $4 million in cash and $2.5 million in a promissory note to acquire the CTRM business, which includes three marketed products in the United States and Europe as well as manufacturing and production centers in the U.S. and Denmark.
Ref. https://finance.yahoo.com/news/aastrom-completes-acquisition-sanofis-cell-124500645.html
SYN ($1.39) Not sure how long I can hold this now "Long" position. Losing patient quite a bit here seeing so many goodies out-there.
PLUG ($4.37) - I might need to create short positions and continue to short this stock until fully recover. I am way under.
VTUS - Big Swing Trade Ideas for Monday, June 2 With Huge Gain Potential
Now, let's look at Ventrus Biosciences, a development-stage specialty pharmaceutical company focusing on the late-stage development and commercialization of gastrointestinal products in the U.S.
Ventrus traded lower on Friday by 1 cent, down 0.79%, and closed at $1.26 per share.
Friday's range: $1.14 - $1.31
52-week range: $0.85 - $4.69
Friday's volume: 1,306,784
3-month average volume: 596,155
Ref. http://www.thestreet.com/story/12729012/2/big-swing-trade-ideas-for-monday-june-2-with-huge-gain-potential.html
I see possible breakout above $1.86. This could have a target of $2.30s -$2.34 (near term)here.
LIQD ($1.60) WATCH for possible breakout above $1.86. This could have a target of $2.34 (near term).
BTW: Nice ending today LIQD!
BODY - Eye balling this tomorrow along with VTUS.
TLOG - Good entry and good closing day fam401!
ARIA - Still looking at EOD here..pretty chunky profit Horent135!
MNGA - Holding well. Unlike the usual where it gives up it's gain. BUT recently it's holding up well. That's telling me something I guess...hang on for the ride.
ETRM - Glad that some of your men escaped out alive! ASTM indeed excellent work there! Overall I try best staying away from BIO recently. IN the case for VTUS..I might have to get back onboard.
IGC ($1.58) Price check. I am still behind.
NEWL ($1.06) Perhaps now is time for revenge. Are we at the bottom yet? $192 previous lost might now be $300-$400 gains..hmmm time for revenge (maybe)
MNGA very soon. Seeing some serious action here right now.
MNGA - Hope to see $1.80-$1.88 today.
BODY - Spec of buy out and keeping the share price $1+ in compliance with NASDAQ still lingers on my mind here. 8.5% stake in Body Central is no joke..in addition look at INUV on news to retain AMEX listing..something to reflect on..
VTUS - Still on radar it's been $1.18 -$1.20 ( I feel comfy) after previous cool down.
MNGA ($1.75) I still have hope for #$1.80-$1.88 <link back>
BODY - I am thinking of going back in Hesse...very soon.
Thanks cintrix!
NEON $3.16 -10.48% - Bottom play?
NEON ($3.23) NON_BIO - CEO Thomas Erikkson bought 100K shares today at $3.07.
Perhaps this will be a bounce play here.
Ref. http://seekingalpha.com/news/1780393-neonode-pares-losses-after-ceo-discloses-fresh-purchase
Very nice Matt! I am sitting average $1.60..perhaps I will load some more soon.
LIQD - I am looking for possible breakout above $1.86. I think once it hits $1.87 it will be explosive move up.
ONCS ($0.90) OncoSec Medical Presents Positive Phase 2 Interim Data Evaluating ImmunoPulse in Melanoma
Data Presented at 2014 ASCO Annual Meeting Suggest ImmunoPulse is Well-Tolerated and Has a Systemic Anti-Tumor Response
Ref. http://finance.yahoo.com/news/oncosec-medical-presents-positive-phase-133100605.html
CTIX ($1.70) Cellceutix Completes Patient Enrollment in Clinical Trial of Prurisol
Brilacidin Phase 2b Trial 60 Percent Enrolled, Seventh Cohort Complete in Cancer Drug Trial
BEVERLY, MA--(Marketwired - Jun 2, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, reports today that patient enrollment has been completed in the Company's Phase 1 crossover study of its anti-psoriasis drug candidate Prurisol. Cellceutix expects lab results, pharmacokinetic studies, and analysis to take approximately two months. If the data shows bioequivalence of Prurisol with Abacavir Sulfate, the Company will then schedule a meeting with the U.S. Food and Drug Administration regarding initiating a Phase 2/3 trial of Prurisol through the 505(b)(2) regulatory pathway.
Ref. http://finance.yahoo.com/news/cellceutix-completes-patient-enrollment-clinical-110000649.html
GTXI (correction)
GXTI - Bummer that would have been very nice Swamp!
INUV ($1.00) Hit it's dolla holla. Very too bad that I did not take position when I knew this was about to hit $1. Shoulda woulda and coulda. Congrats to those that took on INUV and nice bounce.
MNGA ($1.71) - $1.80 - $1.88 might be possible who knows.
INUV - Always good news to able to retain full listing on NYSE.